By Michael Erman and Julie Steenhuysen Aug 19 (Reuters) - Moderna said on Wednesday that a personalized mRNA cancer vaccine ...

Adding the personalized mRNA therapy intismeran autogene to Keytruda cut melanoma recurrence and spread risk after surgery, a Phase 3 trial found. A Phase 3 trial found that adding the individualized ...

In the Phase 3 EV-304 trial, statistically significant improvements in overall survival and pathological complete response were also observed, with over half of patients having no detectable disease ...

The personalised cancer vaccine was given alongside Merck’s immunotherapy Keytruda to patients whose melanoma had been ...

Moderna and Merck’s mRNA cancer vaccine, combined with Keytruda, showed promise in preventing melanoma recurrence, according ...

Merck and Moderna’s success with a personalized cancer vaccine designed to keep melanoma at bay opens a ​new avenue of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

New KEYTRUDA indications are expected to preserve Merck's top line, significantly aided by the high single-digit Animal Health/Livestock and the triple-digit Winrevair revenue growth in FY2025.

By Julie Steenhuysen and Michael Erman CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with ...

Merck and Moderna’s success with a personalised cancer vaccine designed to keep melanoma at bay opens a new avenue of ...